Analysts predict that Davita Inc (NYSE:DVA) will announce sales of $2.92 billion for the current quarter, according to Zacks. Six analysts have made estimates for Davita’s earnings. The lowest sales estimate is $2.86 billion and the highest is $2.95 billion. Davita posted sales of $2.82 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.5%. The firm is expected to issue its next quarterly earnings results on Wednesday, February 12th.
According to Zacks, analysts expect that Davita will report full-year sales of $11.41 billion for the current financial year, with estimates ranging from $11.35 billion to $11.45 billion. For the next financial year, analysts anticipate that the company will post sales of $11.48 billion, with estimates ranging from $11.33 billion to $11.65 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Davita.
Davita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $1.53 EPS for the quarter, topping the consensus estimate of $1.24 by $0.29. Davita had a return on equity of 19.95% and a net margin of 3.68%. The business had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the previous year, the firm earned $0.56 EPS. The company’s quarterly revenue was up 2.0% compared to the same quarter last year.
Several research firms have recently commented on DVA. UBS Group cut their price objective on Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. Wolfe Research downgraded Davita from an “outperform” rating to a “market perform” rating and set a $57.00 price objective for the company. in a research report on Friday, October 25th. ValuEngine downgraded Davita from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. SunTrust Banks raised their price objective on Davita to $72.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Finally, Raymond James downgraded Davita from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $65.00.
Shares of NYSE DVA traded down $0.53 during trading on Monday, hitting $72.71. 1,214,509 shares of the company were exchanged, compared to its average volume of 1,401,824. Davita has a 12-month low of $43.40 and a 12-month high of $73.91. The company has a debt-to-equity ratio of 4.26, a quick ratio of 1.77 and a current ratio of 1.81. The company has a fifty day moving average price of $68.41 and a 200-day moving average price of $59.00. The firm has a market capitalization of $9.30 billion, a PE ratio of 20.37, a P/E/G ratio of 0.60 and a beta of 1.67.
Large investors have recently modified their holdings of the stock. Flinton Capital Management LLC grew its position in Davita by 3.3% in the 2nd quarter. Flinton Capital Management LLC now owns 187,884 shares of the company’s stock valued at $10,571,000 after acquiring an additional 6,052 shares in the last quarter. Sciencast Management LP acquired a new position in Davita in the 3rd quarter valued at about $1,017,000. Bank of Hawaii acquired a new position in Davita in the 3rd quarter valued at about $430,000. Wedge Capital Management L L P NC grew its position in Davita by 28.8% in the 2nd quarter. Wedge Capital Management L L P NC now owns 37,691 shares of the company’s stock valued at $2,120,000 after acquiring an additional 8,434 shares in the last quarter. Finally, Tibra Equities Europe Ltd acquired a new position in Davita in the 3rd quarter valued at about $1,141,000. 94.04% of the stock is owned by hedge funds and other institutional investors.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: Forex
Get a free copy of the Zacks research report on Davita (DVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.